FIELD: biotechnology.
SUBSTANCE: following is proposed: the use of the human thioredoxin-1 (Trx1) antigen epitope consisting of the amino acid sequence of the following SEQ ID NO: 174, for specific binding to a monoclonal antibody or antigen-binding fragment thereof, which contains a light chain variable region containing a CDR1 of the following SEQ ID NO: 1, CDR2 with the following SEQ ID NO: 2, CDR3 with the following SEQ ID NO: 3 and a heavy chain variable region containing CDR1 of the following SEQ ID NO: 4, CDR2 with the following SEQ ID NO: 5, CDR3 with the following SEQ ID NO: 6.
EFFECT: epitope can be used to develop an antibody with improved Trx1 binding affinity, high level of sensitivity and specificity, which is useful for diagnosing breast cancer.
3 cl, 22 dwg, 25 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2790687C2 |
| MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2791264C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THIOREDOXIN-1 AND ITS USE | 2016 |
|
RU2747929C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
